Objectives: To study the correlations of genetic variants of tenofovir tubular transporters, plasma tenofovir concentrations and clinical factors with decreased glomerular filtration rate in HIV-infected patients who received tenofovir.
Introduction
Renal complications are increasingly prevalent in HIV-infected patients and are considered to be a major cause of morbidity and mortality in the era of widespread use of combined antiretroviral therapy (ART). 1, 2 Tenofovir-containing regimens have been recommended as first-line antiretroviral therapy. 3, 4 Theoretically, structural similarity between tenofovir and other previous acyclic nucleotide analogues, i.e. cidofovir and adefovir, establishes concerns regarding renal tubular dysfunction. 5 Tenofovir may be toxic to mitochondria of the proximal renal tubular cells, leading to compromised renal tubular cell integrity, subsequent tubular necrosis and a decreased glomerular filtration rate. 6 Previously reported risk factors for tenofovir-associated renal toxicity include concurrent renal toxic drugs and protease inhibitors, low baseline CD4 cell count, older age, low body weight and ABCC2 gene polymorphisms.
6 ABCC2*1C c.224C.T, encoding multidrug resistance-associated protein 2 (MRP2) on the luminal surface of renal tubular cells, has been associated with renal tubular dysfunction. Data regarding the effect of this polymorphism on glomerular function are still limited. P-glycoprotein, encoded by ABCB1, is a protein expressed on the luminal surface of renal tubular cells that excrete the prodrug of tenofovir into the urine. 7 Inherited differences in the transporter of tenofovir also play a role. On the other hand, the intracellular tenofovir concentration was previously shown to be associated with efficacy and toxicity. 8 However, the study of intracellular tenofovir pharmacokinetics is relatively complex. A few studies have reported that tenofovir-associated renal toxicity is related to plasma drug concentrations in animals and humans. 9, 10 Early detection of risk factors and establishment of a practical screening tool for monitoring and early detection of tenofovir-associated renal complications would be beneficial. To date, clinical trials regarding genetic variants of tenofovir tubular transporters incorporated with plasma tenofovir concentration and clinical factors that are associated with decreased renal clearance are relatively limited, especially in Asians.
Patients and methods

Study design
This study was a prospective, open-label trial involving 117 ART-naive HIV-infected patients at the Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand. The Institutional Ethics Committees of the Bamrasnaradura Infectious Diseases Institute approved this study. All patients provided written, informed consent prior to enrolment. The primary objective was to study predictive factors of a decreased glomerular filtration rate at 48 weeks of a tenofovircontaining antiretroviral regimen, including genetic variants of tenofovir tubular transporters, plasma tenofovir concentrations and clinical factors. The secondary objectives were to study the following: (i) glomerular filtration rate changes over a 96 week study period; (ii) the correlation between genetic variants of tenofovir tubular transporters incorporated with clinical factors and plasma tenofovir concentrations; and (iii) predictive factors of a decreased glomerular filtration rate at 96 weeks of a tenofovircontaining antiretroviral regimen. The enrolment period of this study was between 2009 and 2011. Inclusion criteria were patients infected with HIV who were: (i) 18-60 years of age; (ii) naive to ART; and (iii) having a CD4 cell count ,350 cells/mm 3 . Exclusion criteria were as follows: (i) a serum creatinine level .2× the upper limit of the normal range; (ii) serum aspartate aminotransferase and alanine aminotransferase levels .5× the upper limit of the normal range; (iii) lost to follow-up before week 12; (iv) receiving nephrotoxic drugs; and (v) being pregnant.
A once-daily ART regimen of 300 mg of tenofovir, 300 mg of lamivudine and 600 mg of efavirenz had been given. The patients had follow-up visits at week 2, week 6, week 12 and every 12 weeks until 96 weeks after ART initiation, at which time they were assessed clinically and/or blood samples were taken. Adherence counselling was provided to the patients and adherence to treatment was assessed with a questionnaire. Any patient with an adherence of ,80% was excluded from the analysis. In addition, patients were instructed to take antiretroviral drugs regularly ≥2 weeks prior to blood collection. Demographic, clinical and laboratory data were recorded before and after ART initiation.
At baseline (week 0), blood samples were obtained to study CD4 cell counts by flow cytometry using monoclonal antibodies with a three-colour reagent (TriTEST; Becton Dickinson BioSciences, San Jose, CA, USA) and a FACScan flow cytometer (Becton Dickinson BioSciences). The HIV-1 RNA viral load was evaluated by real-time PCR using a COBAS AmpliPrep/ COBAS TaqMan HIV-1 test (Roche Molecular Systems, Branchburg, NJ, USA) that measures plasma HIV-1 RNA in the range of 40 -10 000 000 copies/mL. At week 24, the plasma tenofovir concentration at 12 h after dosing was measured. The estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease (MDRD) study equation. At week 24, plasma phosphate, spot urine creatinine, spot urine phosphate and plasma calcium were measured under fasting conditions. The study formula fractional excretion of phosphate (FEphos) was calculated. Urine protein and urine glucose were tested using a random sample of urine and a dipstick test. Positive urine protein and urine glucose of .1+ was classified as proteinuria and glycosuria, respectively.
With regard to genotyping of transporter genes, blood samples at baseline were submitted to the Laboratory for Pharmacogenomics and Personalized Medicine, Ramathobidi Hospital, Mahidol University for pharmacogenetic analysis. Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA, USA) were used to genotype ABCC2*1C c.224C.T (rs717620; assay ID C_2814642_10) and ABCB1*6 c.3435C.T (rs1045642; assay ID C_7586657_20). These SNPs were genotyped using an allele-specific fluorogenic 5
′ nuclease chain reaction assay with predesigned primers and TaqMan MGB probes (TaqMan SNP Genotyping Assay; Applied Biosystems). Sequence-specific forward and reverse primers to amplify the polymorphic sequence of interest used two TaqMan MGB probes; one probe was labelled with VIC dye and detected the allele 1 sequence and the second probe was labelled with FAM dye and detected the allele 2 sequence.
Quantitative determination of the plasma tenofovir concentration was performed at the HIV Netherlands-Australia-Thailand Pharmacology Laboratory involving protein precipitation extraction followed by HPLC with fluorescence detection. This method was originally developed at the Clinical Pharmacy Laboratory, Radboud University, Nijmegen, The Netherlands. The target concentration range for the calibration curves was 1.5 -150. The accuracy of tenofovir from biological fluid was determined by using at least 5 samples for 5 concentration levels, i.e. lowest limit of quantification, low, medium, high and the highest limit of quantification. This was carried out on three separate days. The percentage accuracy was determined by comparing the concentration of the samples from the experiment with the amount used. The percentage accuracy should be within 80% -120%. Within-day and between-day precision was calculated to express the precision under the same operating conditions over a certain period of time. This was carried out on three separate days. The precision of four tenofovir samples was determined by using at least five samples for five concentration levels, i.e. lowest limit of quantification, low, medium, high and the highest limit of quantification.
Statistical analysis
Mean (+SD), median (IQR) and frequency (%) were used to describe patients' characteristics and measurements. The independent variables were evaluated with simple linear regression to identify the factors that were associated with decreased eGFR. By bivariate analysis, any independent variable with a P value of ,0.1 was entered into a model of multiple regression analysis. The regression coefficient (b value) and its 95% CI for each factor were computed. All parameters except sex, hepatitis B virus antigen and single nucleotide polymorphisms (SNPs) were treated as continuous variables. The independent parameters that were strongly correlated between each other were not analysed in the same multivariate analysis model. A positive regression weight for each factor means a onepoint increase in factor results in an increase of b value of 1 U of eGFR.
A negative weight has the opposite interpretation. Paired sample t-tests were used to compare mean eGFRs at particular weeks. Student's t-tests were used to compare mean eGFRs between SNPs. Interpatient variability of the plasma tenofovir concentration was expressed as the coefficient of variation (CV%). All analyses were performed using SPSS version 15.0 (SPSS, Chicago, IL, USA). A P value of ,0.05 was considered statistically significant.
Results
For 117 patients, the mean+SD age was 37.6+8.6 years, 90 (77%) patients were men, the median (IQR) CD4 cell count was 42 (17 -114) cells/mm 3 and the median (IQR) plasma HIV-1 RNA was 5.8 (5.4 -6.3) log copies/mL. Table 1 shows all demographics and laboratory parameters of the study patients at baseline. At week 24, the mean+SD plasma tenofovir concentration at 12 h after dosing was 105.0+46.4 ng/mL and the interpatient variability was 44.2%. At week 24, the mean+SD plasma phosphate was 3.7+0.8 mg/dL, the mean+SD plasma calcium was 9.0+1.7 mg/dL, the mean+SD urine phosphate was 55.6+34.8 mg/dL and the mean+SD urine creatinine was 132.5+71.6 mg/dL. The mean+SD percentage of FEphos at week 24 was 11.3%+9.2%. Ninety-nine (84.6%), 50 (42.7%) and 21 (17.9%) patients had percentages of FEphos .5%, .10% and .15%, respectively. There were no differences in FEphos between the patients with ABCC2*1C genotype CC and those with CT/TT (P .0.05). Tables 2 and 3 show the univariate and multivariate analyses of possible predictive factors for decreased eGFR MDRD at week 48 and week 96, respectively. Overall, the dependent variable 'decreased eGFR' was associated with ABCC2*1C, high plasma tenofovir concentration, low eGFR MDRD at baseline and older age (all P, 0.05). There was no correlation between ABCC2*1C and eGFR MDRD at baseline (P ¼ 0.148). The relationship between eGFR MDRD at week 48 and plasma tenofovir concentrations by ABCC2 polymorphisms is displayed in Figure 1 . The coefficient of determination between eGFR MDRD at week 48 and plasma tenofovir concentrations was 0.134 and the P value was 0.065. Figure 2(a) compares the mean eGFR MDRD at baseline and subsequent weeks. There were significant changes of eGFR MDRD at both week 48 and week 96 (both P,0.001). Figure 2(b) compares the mean eGFR MDRD at week 48 and mean plasma tenofovir concentrations between ABCC2*1C genotype CC versus CT/TT and ABCB1*6 genotype CC versus CT/TT. Mean+SD plasma tenofovir concentrations in ABCC2*1C genotypes CC and CT/TT were 113.7+46.8 and 93.3+43.8 ng/mL, respectively (P ¼ 0.018). Mean+SD tenofovir concentrations in those patients who carried ABCB1*16 genotypes CC and CT/TT were 96.5+40.8 and 108.2+48.5 ng/mL, respectively (P¼ 0.226). Table 4 shows univariate and multivariate analyses of predictive factors for increased plasma tenofovir concentrations. The factors low body weight, ABCC2*1C genotype CC and low CD4 cell count were independently associated with high plasma tenofovir concentrations (all P, 0.05). Three percent (3 of 117) and 4% (5 of 110) had proteinuria at 48 and 96 weeks, respectively. One percent (1 of 117) and 0% (0 of 110) had glycosuria at weeks 48 and 96, respectively. All patients had completed follow-up at 48 weeks, but seven patients (five lost to follow-up, one transferred out and one died) had not done so at 96 weeks.
Discussion
The efficacy and durability of tenofovir-containing antiretroviral regimens outweigh their renal toxicity. Nonetheless, any prediction that can identify those patients at risk of renal complications would be beneficial because of the incomplete reversibility of tenofovir-associated renal dysfunction after drug discontinuation. 11, 12 Renal tenofovir clearance is via a combination of glomerular function and active tubular secretion. 13 Impaired renal function may present as acute renal injury, chronic kidney disease and decreased glomerular filtration rate. 6 The present study has demonstrated that eGFR persistently declined over the 2 year study period and ABCC2*1C genotype CC at position 224 was a strong predictive factor of both decreased eGFR and high plasma tenofovir concentrations in HIV-infected patients. Tenofovir exits across the luminal surface of renal proximal tubular cells via MRP2, which is encoded by ABCC2. 13, 14 Polymorphisms in ABCC2 have been reported to be associated with proximal tubular dysfunction in previous studies with relatively small patient numbers. 15, 16 A more recent report showed that SNPs in ABCC2 were associated with tenofovir-induced tubulopathy in Japanese patients. 17 The present study is the second report in Asian ethnicity. In addition, the present study showed that ABCC2*1C genotype CC at position 224 is also associated with decreased eGFR. To date, the mechanism of MRP2 influence on renal dysfunction has not been conclusively determined. A hypothesis has been proposed. Tenofovir is removed from proximal tubular cells via the luminal surface less effectively in patients carrying ABCC2 224C homozygosity. This leads to an accumulation of the intracellular tenofovir concentration. Of note, a higher plasma tenofovir concentration is also found to ABCC2 and renal dysfunction be related to ABCC2*1C genotype CC. Moreover, this study showed that a higher plasma tenofovir concentration at 12 h after dosing is a significant intermediate marker of decreased eGFR. A previous study in Caucasians showed high trough tenofovir concentrations of 182 ng/mL in patients with renal tubular dysfunctions and trough tenofovir concentrations of 106 ng/mL in patients without renal tubular dysfunction. 10 In addition, having a trough plasma tenofovir concentration .160 ng/mL was associated with a five times increased risk of developing renal dysfunction. 10 A nonnucleoside reverse transcriptase inhibitor was used as a component of the study antiretroviral regimen. Plasma concentrations of tenofovir even increase when it is co-administered with some ritonavir-boosted protease inhibitors. 18 Likewise, the same regimen used in this study eliminated the confounding factor from a different concomitant drug. On the other hand, P-glycoprotein, encoded by ABCB1, is another protein expressed on the apical membrane of proximal tubular cells that excrete this drug into the urine. 7 The ABCB1*6 c.3435C.T polymorphism was not found to be associated with either decreased eGFR or high tenofovir concentration. A previous study in Japanese patients did not reveal an association between this SNP and tubulopathy. 17 Other significant predictive factors found in the present study include pre-existing renal impairment and older age. Therefore, tenofovir should be used with caution in patients who have such predisposing factors. However, another approach to identify patients at risk of tenofovir-associated renal toxicity is still warranted. No clinically significant hypophosphataemia or Fanconi syndrome was found in these patients who were proven to have urinary phosphate loss. According to the grading system, severe hypophosphataemia is defined as plasma phosphate ,1.0 mg/dL and determination of the phosphate level should be performed after 12 h fasting. 19 Theoretically, detection of a mild derangement of renal proximal tubular function is relatively difficult because urinary phosphate loss is usually compensated by bone loss to maintain the plasma phosphate level. This probably explains the reason why phosphataemia remained normal in this study.
A number of study limitations should be acknowledged. First, polymorphisms at genes encoding transporter proteins, such as organic anion transporter and other multidrug resistance proteins (MRPs), at the basolateral surface and luminal surface of proximal renal tubular cells had been reported to be associated with tubular dysfunction. 15 In addition, genetic variants of ABCC10 have been recently reported to be associated with renal tubular dysfunction. 20 Second, only a single timepoint of plasma tenofovir measurement per patient was performed. Intrapatient variation of tenofovir clearance has been reported. 21 Several reports demonstrated tenofovir-related renal toxicity after widespread use in real-life clinical practice, although this drug was generally safe and well tolerated in pre-marketing clinical trials. 22 -24 In a recent meta-analysis of 17 studies regarding the renal safety of tenofovir in HIV-infected patients, a reduction of renal function and an increased risk of renal failure were reported. 25 Nevertheless, the evident virological and immunological responses achieved with tenofovir-containing antiretroviral regimens outweigh such harm. Lastly, some potential risk factors associated with renal impairment are lacking, such as diabetes, hypertension and opportunistic infections.
In summary, the present study provides promising data in terms of the association between SNPs in ABCC2 incorporated with tenofovir exposure and tenofovir-associated decreased glomerular function in Asian HIV-infected patients. A practical screening tool for the monitoring and early detection of tenofovirassociated renal complications of this pharmacogenetic marker would be beneficial, particularly in patients who are elderly and have impaired baseline renal function. Manosuthi et al.
